Johnson & Johnson (JNJ), Thursday announced results from additional analyses of the Phase 2 DAHLIAS study, evaluating the effects of Nipocalimab in participants with primary Sjogren's disease, a chronic autoimmune disease.
The data showed improvement in key measures of disease activity, and IgG reduction by over 77 percent following treatment.
The study achieved the primary endpoint with patients showing improvement in the ClinESSDAIa score at 24 weeks.
Additionally, key secondary endpoints were met, indicating reduced disease activity both systemically and across multiple organ systems, as well as improvements in physician assessments and composite SjD assessment tools, the company stated.
Currently, JNJ's stock is trading at $151.21, down 1.34 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.